Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Home Office 650x80px
Document › Details

Adrenomed AG. (9/26/19). "Press Release: Adrenomed Completes Full Enrollment with 300 Patients in AdrenOSS-2 Trial with Adrecizumab in Septic Shock". Hennigsdorf.

Organisations Organisation Adrenomed AG
  Organisation 2 Radboud University Medical Centre Nijmegen (RUMC)
  Group University of Nijmegen (Radboud University)
Products Product sphingotest® bio-ADM®
  Product 2 phase 2 study
Persons Person Schneider-Mergener, Jens (Adrenomed 201908– CEO before 3B BPharmaceuticals + Phavaris + Jerini)
  Person 2 Bergmann, Andreas (Sphingotec GmbH 201301 Managing Director)
     


> Proof-of-concept Phase II trial AdrenOSS-2 is assessing first-in-class antibody Adrecizumab, designed to restore and maintain vascular integrity

> AdrenOSS-2 trial design and Adrecizumab mode of action will be presented at the European Society of Intensive Care Medicine (ESICM) annual congress, LIVES

> Top-line study results are expected in Q1 2020

Hennigsdorf/Berlin (Germany), September 26, 2019 – Adrenomed AG, the vascular integrity company, announced today the successful completion of patient enrollment in the proof-of-concept Phase II trial, AdrenOSS-2, evaluating Adrecizumab in patients with early septic shock. Adrecizumab is a first-in-class antibody targeting the vasoprotective peptide Adrenomedullin to restore and maintain vascular integrity in life-threatening conditions associated with vascular leakage, congestion and shock.

Three hundred patients with early septic shock and elevated blood levels of Adrenomedullin (bio-ADM®), have been randomized in the multicenter, double-blind, placebo-controlled AdrenOSS-2 trial (NCT03085758). The study’s primary endpoints are safety and tolerability of Adrecizumab over a 90-day period; key secondary endpoints are the Sepsis Support Index (SSI), defined as days with organ support or death within 14 days and mortality at day 28. Top-line results from the trial are expected in the first quarter of 2020.

“Adrenomed is pleased to announce the completion of patient enrollment in our proof-of concept Phase II trial, reaching another important step in the development of our drug candidate. Sepsis remains the major life-threatening condition in ICU,” commented Jens Schneider-Mergener, CEO of Adrenomed AG.

CSO Andreas Bergmann added: “With Adrecizumab, we are pursuing a new strategy to fight sepsis and septic shock. By restoring and preserving vascular integrity, we aim to provide physicians with a new therapy to improve outcomes for their patients with this devastating disease.”

“The research into the pathogenesis of sepsis has traditionally focused on the immune response. During the last decade, a fundamental rethinking has taken place and the breakdown of vascular integrity now is considered to play a crucial role in the development of sepsis,” commented Prof. Dr. Peter Pickkers, Radboud University, Department of Intensive Care, Nijmegen, The Netherlands. “Adrecizumab targets the vasoprotective peptide Adrenomedullin, a key regulator of vascular integrity, in order to restore and preserve the endothelial barrier function.”

Prof. Dr. Pickkers will present the AdrenOSS-2 trial design and Adrecizumab’s mode of action in the talk “Adrenomedullin in sepsis, effect of the non-inhibitory antibody Adrecizumab,” during the session, “Innovation in sepsis treatment,” at the 32nd European Society of Intensive Care Medicine (ESICM) LIVES annual congress in Berlin, on October 1st, 16:20 CEST.


About Adrenomed

Adrenomed AG is a German privately financed, clinical-stage biopharmaceutical company. Adrenomed´s mission is to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options. Founded in 2009 by a management team with decades of in-depth experience in sepsis and deep knowledge in diagnostics and drug development, the company’s lead product candidate Adrecizumab is a first-in-class monoclonal antibody. Adrecizumab targets the vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity. Adrecizumab is currently under clinical evaluation in a biomarker-guided, double-blinded, placebo-controlled, randomized, multicenter proof-of-concept Phase II trial with 300 patients suffering from septic shock. Excellent safety and tolerability were demonstrated in two Phase I trials. For further information, please visit www.adrenomed.com or see our LinkedIn profile Adrenomed AG.


Contact

Adrenomed AG
Frauke Hein, Ph.D. (Chief Business Officer)
phone: +49 (0)3302 2077814
fhein@adrenomed.com

Media Inquiries
MC Services AG
Eva Bauer/Julia von Hummel
phone: +49 (0)89 21022880
adrenomed@mc-services.eu

   
Record changed: 2020-02-24

Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 650x65px

More documents for Adrenomed AG


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px




» top